Articles By Jack Cush, MD
Factors Associated with COVID-19 Deaths in Rheumatic Patients
Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.
Read Article
RheumNow Podcast – Myth Busters (5.21.2021)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
Tocilizumab Risk of Diverticulitis and GI Perforation
A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA
Read Article
Total Ankle Arthroplasty vs. Arthodeisis?
The Journal of Bone & Joint Surgery reports the findings of a 4-year trial comparing outcomes of total ankle arthroplasty (TAA) versus ankle arthrodesis (AA) in patients with severe ankle arthritis; finding that while both groups improved, TAA was associated with less pain and better function after 4 years.
Read Article
Checkpoint Inhibitor Safety in Melanoma Patients with Autoimmune Disease
Immune checkpoint inhibitors (ICI) are well known to cause immune-related adverse events (irAEs). A study from the Dutch Melanoma Treatment Registry shows that the use of checkpoint inhibitors for advanced melanoma in AID (autoimmune disease) patients did not increase the risk of irAEs, except for those with preexisting IBD.
Read Article
Severity Associated with Erosive Hand Osteoarthritis
Erosive hand osteoarthritis (EHOA) was studied as part of the Osteoarthritis Initiative, and shown to increase with advanced age and female sex, with developmental findings to suggest that EHOA as a disorder of skeletal frailty.
Read Article
Anifrolumab Reduces Lupus Flares
Anifrolumab has been studied in two large phase 3 trials in systemic lupus erythematosus (SLE) patients; pooled data from both the TULIP-1 and TULIP-2 trials were used to show that anifrolumab reduces flares in patients with moderate to severe SLE.
Read Article
IL-23 Inhibitor Tildrakizumab Effective in Psoriatic Arthritis
Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death.
Read Article
RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists. We love Rheumatology!
Read Article
RheumNow Live 2021 Now Available for All
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
Read Article
